Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Infection with COVID-19 does not increase blood pressure in patients with chronic kidney disease

Journal of Human Hypertension volume 39, pages 777–783 (2025) Cite this article

Subjects

Abstract

The association between hypertension (HTN) and COVID-19 in patients with chronic kidney disease (CKD) has not been completely elucidated. We aimed to study the effect of COVID-19 on HTN severity in patients with CKD. Included in the analysis were all adults, insured by Maccabi Healthcare Services, a large-scale Health Maintenance Organization, who were registered as having CKD on 1.7.2023. Patients in the study group had a confirmed SARS-CoV-2 infection during the study period (2020–2022), whereas patients in the control group did not. The infection date was defined as T0 for the study group, whereas T0-f-COVID denotes a matched time point for controls. We compared the differences in blood pressure values between pre- and post- T0 in both groups. A group of 85,502 CKD patients with documented COVID-19, of which 43,875 patients had at least two blood pressure (BP) measurements documented, both prior to and after T0 (study group). The control group of 136,645 CKD patients had no documented COVID-19 cases, and 58,874 had similarly documented BP measurements. On average, there were six BP measurements during the study period in both groups. The average BP values in the study group decreased by 1 mmHg systolic and 0.6 mmHg diastolic following COVID-19 (P value 0.03 and 0.004, respectively). The difference in BP values in the control group was −0.8 mmHg and −0.6 mmHg for systolic and diastolic BP (p < 0.001 for both values). Contrary to previous studies, our data demonstrated that BP does not increase following COVID-19 in patients with CKD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
The alternative text for this image may have been generated using AI.
Fig. 2: BP before and after COVID-19.
The alternative text for this image may have been generated using AI.
Fig. 3: Changes in Blood Pressure.
The alternative text for this image may have been generated using AI.

Similar content being viewed by others

Data availability

All relevant data is included in the manuscript. Additional data may be available per request from the corresponding author.

References

  1. Thakkar J, Chand S, Aboodi MS, Gone AR, Alahiri E, Schecter DE, et al. Characteristics, outcomes and 60-Day hospital mortality of ICU patients with COVID-19 and acute kidney injury. Kidney360. 2020;1:1339–44.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574–81.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Ann Tallant E, et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005;68:2189–96.

    Article  PubMed  CAS  Google Scholar 

  9. South AM, Tomlinson L, Edmonston D, Hiremath S, Sparks MA. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020;16:305–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Ahmadian E, Hosseiniyan Khatibi SM, Razi Soofiyani S, Abediazar S, Shoja MM, Ardalan M, et al. Covid-19 and kidney injury: Pathophysiology and molecular mechanisms. Rev Med Virol. 2021;31:e2176.

    Article  PubMed  CAS  Google Scholar 

  11. Kamalumpundi V, Kawasaki S, Cheng L, Meyers EE, Shams E, Ofori O, et al. Association between renin-angiotensin antagonism and COVID-19-related mortality in patients with essential hypertension: A single center, retrospective cohort study. J Clin Hypertens (Greenwich). 2024;26:1039–44.

    Article  PubMed  CAS  Google Scholar 

  12. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28:583–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Petersen EL, Gossling A, Adam G, Aepfelbacher M, Behrendt CA, Cavus E, et al. Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme. Eur Heart J. 2022;43:1124–37.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899–911.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Zuin M, Rigatelli G, Bilato C, Pasquetto G, Mazza A. Risk of incident new-onset arterial hypertension after COVID-19 recovery: a systematic review and meta-analysis. High Blood Press Cardiovasc Prev. 2023;30:227–33.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Delalic D, Jug J, Prkacin I. Arterial Hypertension Following Covid-19: a retrospective study of patients in a Central European Tertiary care center. Acta Clin Croat. 2022;61:23–7.

    PubMed  PubMed Central  Google Scholar 

  17. Zhang V, Fisher M, Hou W, Zhang L, Duong TQ. Incidence of new-onset hypertension Post-COVID-19: comparison with influenza. Hypertension. 2023;80:2135–48.

    Article  PubMed  CAS  Google Scholar 

  18. Georgianos PI, Agarwal R. Hypertension in chronic kidney disease-treatment standard 2023. Nephrol Dial Transplant. 2023;38:2694–703.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Trimarco V, Izzo R, Pacella D, Trama U, Manzi MV, Lombardi A, et al. Incidence of new-onset hypertension before, during, and after the COVID-19 pandemic: a 7-year longitudinal cohort study in a large population. BMC Med. 2024;22:127.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Gotanda H, Liyanage-Don N, Moran AE, Krousel-Wood M, Green JB, Zhang Y, et al. Changes in blood pressure outcomes among hypertensive individuals during the COVID-19 Pandemic: a time series analysis in three US healthcare organizations. Hypertension. 2022;79:2733–42.

    Article  PubMed  CAS  Google Scholar 

  21. Wojciechowska W, Rajzer M, Kreutz R, Weber T, Bursztyn M, Persu A, et al. The impact of the COVID-19 pandemic on blood pressure control in patients with treated hypertension-results of the European Society of Hypertension Study (ESH ABPM COVID-19 Study). J Hypertens. 2024;42:2065–74.

    Article  PubMed  CAS  Google Scholar 

  22. Schmidt-Lauber C, Alba Schmidt E, Hanzelmann S, Petersen EL, Behrendt CA, Twerenbold R, et al. Increased blood pressure after nonsevere COVID-19. J Hypertens. 2023;41:1721–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Bar-Or I, Indenbaum V, Weil M, Elul M, Levi N, Aguvaev I, et al. National scale real-time surveillance of SARS-CoV-2 variants dynamics by wastewater monitoring in Israel. Viruses. 2022;14:1229.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Russell CD, Lone NI, Baillie JK. Comorbidities, multimorbidity and COVID-19. Nat Med. 2023;29:334–43.

    Article  PubMed  CAS  Google Scholar 

  25. Force USPST, Krist AH, Davidson KW, Mangione CM, Cabana M, Caughey AB, et al. Screening for hypertension in adults: US Preventive Services task force reaffirmation recommendation statement. JAMA. 2021;325:1650–6.

    Article  Google Scholar 

  26. Kim R, Nachman S, Fernandes R, Meyers K, Taylor M, LeBlanc D, et al. Comparison of COVID-19 infections among healthcare workers and non-healthcare workers. PLoS One. 2020;15:e0241956.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Stepanova M, Lam B, Younossi E, Felix S, Ziayee M, Price J, et al. The impact of variants and vaccination on the mortality and resource utilization of hospitalized patients with COVID-19. BMC Infect Dis. 2022;22:702.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Paiva AMG, Gomes M, Campana EMG, Feitosa ADM, Sposito AC, Mota-Gomes MA, et al. Impact of hypertension phenotypes on the office and 24-h pulse wave velocity and augmentation index in individuals with or without antihypertensive medication use. Hypertens Res. 2019;42:1989–95.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work received support from Kahn Sagol Maccabi (KSM) Research & Innovation center.

Author information

Authors and Affiliations

  1. Joyce and Irving Goldman School of Medicine, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel

    Avital Angel-Korman, Tal Brosh-Nissimov & Adi Leiba

  2. Nephrology and Hypertension Institute, Samson Assuta Ashdod University Hospital, Ashdod, Israel

    Avital Angel-Korman & Adi Leiba

  3. Faculty of Health Sciences, Tel Aviv University, Tel Aviv, Israel

    Ori Mayer

  4. Infectious Diseases Unit, Samson Assuta Ashdod University Hospital, Ashdod, Israel

    Tal Brosh-Nissimov

Authors
  1. Avital Angel-Korman
    View author publications

    Search author on:PubMed Google Scholar

  2. Ori Mayer
    View author publications

    Search author on:PubMed Google Scholar

  3. Tal Brosh-Nissimov
    View author publications

    Search author on:PubMed Google Scholar

  4. Adi Leiba
    View author publications

    Search author on:PubMed Google Scholar

Contributions

AAK planned the study and wrote the manuscript. OM analyzed the data. TBN helped in data analysis and manuscript editing. AL edited the original manuscript and revised all versions.

Corresponding author

Correspondence to Adi Leiba.

Ethics declarations

Competing interests

The authors declare that they have no affiliations with or involvement in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Angel-Korman, A., Mayer, O., Brosh-Nissimov, T. et al. Infection with COVID-19 does not increase blood pressure in patients with chronic kidney disease. J Hum Hypertens 39, 777–783 (2025). https://doi.org/10.1038/s41371-025-01068-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41371-025-01068-8

Search

Advanced search

Quick links